DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma

Journal of Clinical Oncology

Volumn 21, Issue 14, 2003, Pages 2732-2739

  Lee, Choon Kee ^a   Barlogie, Bart ^a   Munshi, Nikhil ^a   Zangari, Maurizio ^a   Fassas, Athanasios ^a   Jacobson, Joth ^a   Van Rhee, Frits ^a   Cottler Fox, Michele ^a   Muwalla, Firas ^a   Tricot, Guido ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; THALIDOMIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CHROMOSOME ABERRATION; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXICITY; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYELOMA; PRIORITY JOURNAL; REMISSION; SENSORY NEUROPATHY; SINUS BRADYCARDIA; SOMNOLENCE; SYNCOPE; THROMBOEMBOLISM; TREATMENT OUTCOME; CANCER STAGING; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MORTALITY; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PROBABILITY; PROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CONFIDENCE INTERVALS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROBABILITY; PROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 0041629471     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.01.055     Document Type: Article

References (25)

1. Alexanian R, Dimopoulos M: The treatment of multiple myeloma. N Engl J Med 330:484-489, 1994
2. Barlogie B, Hall R, Zander A, et al: High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67:1298-1301, 1986
3. Selby PJ, McElwain TJ, Nandi AC, et al: Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 66:55-62, 1987
4. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med 335:91-97, 1996
5. Cunningham D, Paz-Ares L, Milan S, et al: High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 12:759-763, 1994
6. Barlogie B, Jagannath S, Desikan KR, et al: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55-65, 1999
7. Barlogie B, Desikan R, Eddlemon P, et al: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494, 2001
8. Barlogie B, Tricot G, Anaissie E: Thalidomide in the management of multiple myeloma. Semin Oncol 28:577-582, 2001
9. D'Amato RJ, Loughman MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085, 1994
10. Hideshima T, Chauhan D, Shima Y, et al: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-4950, 2000
11. Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353-1356, 1984
12. Passas AB, Spencer T, Desikan R, et al: Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients. Br J Haematol 119:164-168, 2002
13. National Cancer Institute: Cancer Therapy Evaluation Program: Common Toxicity Criteria, version 2. Bethesda, MD, National Cancer Institute, April 30, 1999
14. Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18:695-706, 1999
15. Hintze JL: Number Cruncher Statistical Systems, May 2002, Kaysville, UT
16. Vesole DH, Crowley JJ, Catchatourian R, et al: High-dose melphalan with autotransplantation for refractory multiple myeloma: Results of a Southwest Oncology Group phase II trial. J Clin Oncol 17:2173-2179, 1999
17. Gertz MA, Lacy MQ, Inwards DJ, et al: Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant 26:45-50, 2000
18. Fermand JP, Ravaud P, Chevret S, et al: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92:3131-3136, 1998
19. Raje N, Powles R, Kulkarni S, et al: A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol 97:153-160, 1997
20. Sirohi B, Powles R, Mehta J, et al: Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system. Br J Haematol 107:656-666, 1999
21. Moreau P, Facon T, Attal M, et al: Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99:731-735, 2002
22. Mineur P, Menard JF, Le Loet X, et al: VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85). Br J Haematol 103:512-517, 1998
23. Zangari M, Siegel E, Barlogie B, et al: Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy. Blood 100:1168-1171, 2002
24. Baidas SM, Winer EP, Fleming GF, et al: Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 18:2710-2717, 2000
25. Molloy FM, Floeter MK, Syed NA, et al: Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 24:1050-1057, 2001